JenaValve Technology, Inc. announced that it has raised $62.5 million in a Series C venture round.
Rox Medical has crossed the halfway point in the CONTROL-HTN international, multi-center, randomized controlled hypertension trial. The milestone was met with the enrollment of the first patient from Prof. Markus van der Giet and Prof. Walter Zidek of the Charite Hospital, Benjamin Franklin Campus, Berlin. The CONTROL-HTN trial is evaluating the Rox Flow procedure — creating a small connection between artery and vein in the upper leg - for the treatment of resistant hypertension.
Parker Laboratories is introducing three, completely redesigned Thermasonic Gel Warmers at RSNA 2013. These include a single bottle gel warmer, a three-bottle gel warmer with preset temperature options and LED indicators, and a three-bottle gel warmer with LCD readout and temperature adjustment in one degree increments, in either Fahrenheit or Celsius.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
In an effort to guide regulation of mobile medical apps, the U.S. Food and Drug Administration (FDA) issued a final guidance document for developers of mobile medical apps.
Medicare expenses for patients with acute myocardial infarction (AMI, heart attack) increased substantially between 1998 and 2008, with much of the increase coming in expenses 31 days or more after the patient was hospitalized, according to a study published by JAMA Internal Medicine, a JAMA Network publication.
Lead study investigators from Icahn School of Medicine at Mount Sinai presented their Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients (PARIS) study findings at the ESC Congress 2013 in Amsterdam organized by the European Society of Cardiology. Their new study results show among patients undergoing percutaneous coronary intervention (PCI) with stents, the risk of cardiovascular complications after stopping dual antiplatelet therapy (DAPT) is highly variable depending on the context, and some patients experience no complications at all.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Siemens’ PETNET Solutions has announced a three-year agreement with The US Oncology Network to supply its entire portfolio of Food and Drug Administration (FDA)-approved positron emission tomography (PET) radiopharmaceutical agents at each of PETNET Solutions’ current Good Manufacturing Practices (cGMP)-certified locations throughout the United States.
Biotronik announced the highly-anticipated results of the Reform study. The study demonstrates that ICD (implantable cardioverter-defibrillator) patients with Biotronik's Home Monitoring can enjoy a reduction in follow-up visits by 58 percent. This in turn leads to patients reporting enhanced quality of life.
In 1988, the first Transcatheter Cardiovascular Therapeutics conference was held with less than 200 attendees in the basement of the Omni Shoreham Hotel in Washington, DC. The first meeting, a forum where physicians came to exchange ideas and compare emerging technologies, featured a single live case transmitted from Georgetown University School of Medicine.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
The U.S. Food and Drug Administration (FDA) announced a final rule for the unique device identification system (UDI) that, once implemented, will provide a consistent way to identify medical devices.
A new study of patients who died of sudden cardiac arrest, a usually fatal condition that causes the heart to stop beating, shows the majority who qualified to receive potentially lifesaving treatment did not receive it.
Physio-Control launched its comprehensive solution designed to improve cardiac resuscitation in hospitals. The CodeManagement Module, which adds capnography and wireless data capabilities to the Lifepak 20/20e defibrillator/monitor platform, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in August and achieved the CE mark for commercialization worldwide in April.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Researchers have determined that fingerstick cardiac troponin I assay testing using the point-of-care i-STAT device is not accurate enough to determine the exact troponin level without the application of a corrective term.
W. L. Gore & Associates has enrolled the first patient in its Gore Carotid Stent clinical study for the treatment of carotid Artery stenosis in patients at increased risk For adverse events From CarOtid enDarterectomy (SCAFFOLD). The patient was successfully treated by Claudio Schönholz, M.D., and his team at the Medical University of South Carolina in Charleston.
GE Healthcare reported that Silent Scan, a revolutionary technology that dramatically quiets magnetic resonance imaging (MRI) exams, is now commercially available and growing in clinical adoption around the world. Silent Scan addresses one of the most significant impediments to patient comfort — excessive acoustic noise generated during an MRI scan. Conventional MRI scanners can generate noise in excess of 110 decibels, roughly equivalent to rock concerts and requiring ear protection. GE’s exclusive Silent Scan technology is designed to reduce MR scanner noise to ambient (background) sound levels and improve a patient’s MRI exam experience.